Tag: mCRPC
AstraZeneca and Merck – Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
RAHWAY, N.J. – AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination with abiraterone plus prednisone significantly improved radiographic progression-free…
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer
This article was originally published here Curr Oncol Rep. 2022 May 16. doi: 10.1007/s11912-022-01278-0. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer….
New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News
HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…
Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer
This article was originally published here Clin Genitourin Cancer. 2021 Jul 31:S1558-7673(21)00151-8. doi: 10.1016/j.clgc.2021.07.012. Online ahead of print. ABSTRACT BACKGROUND: There has been considerable interest in ctDNA next generation sequencing platforms to assess genomic alterations in mCRPC given its accessibility and identification of temporal genomic data. PATIENTSAND METHODS: In this…
